Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.

Abstract:

:Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or TRAIL-receptor agonistic monoclonal antibodies promote apoptosis in most cancer cells, and the differential expression of TRAIL-R2 between tumor and normal tissues allows its exploitation as a tumor-associated antigen. The use of these antibodies as anticancer agents has been extensively studied, but the results of clinical trials were disappointing. The observed lack of anticancer activity could be attributed to intrinsic or acquired resistance of tumor cells to this type of treatment. A possible strategy to circumvent drug resistance would be to strike tumor cells with a second modality based on a different mechanism of action. We therefore set out to generate and optimize a bispecific antibody targeting TRAIL-R2 and CD3. After the construction of different bispecific antibodies in tandem-scFv or single-chain diabody formats to reduce possible immunogenicity, we selected a humanized bispecific antibody with very low aggregates and long-term high stability and functionality. This antibody triggered TRAIL-R2 in an agonistic manner and its anticancer activity proved dramatically potentiated by the redirection of cytotoxic T cells against both sensitive and resistant melanoma cells. The results of our study show that combining the TRAIL-based antitumor strategy with an immunotherapeutic approach in a single molecule could be an effective addition to the anticancer armamentarium.

journal_name

MAbs

journal_title

mAbs

authors

Satta A,Mezzanzanica D,Caroli F,Frigerio B,Di Nicola M,Kontermann RE,Iacovelli F,Desideri A,Anichini A,Canevari S,Gianni AM,Figini M

doi

10.1080/19420862.2018.1494105

subject

Has Abstract

pub_date

2018-10-01 00:00:00

pages

1084-1097

issue

7

eissn

1942-0862

issn

1942-0870

journal_volume

10

pub_type

杂志文章

相关文献

mAbs文献大全
  • Differences in N-glycan structures found on recombinant IgA1 and IgA2 produced in murine myeloma and CHO cell lines.

    abstract::The development and production of recombinant monoclonal antibodies is well established. Although most of these are IgGs, there is also great interest in producing recombinant IgAs since this isotype plays a critical role in providing immunologic protection at mucosal surfaces. The choice of expression system for prod...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.2.3.11802

    authors: Yoo EM,Yu LJ,Wims LA,Goldberg D,Morrison SL

    更新日期:2010-05-01 00:00:00

  • Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.

    abstract::The neonatal Fc receptor (FcRn) is important for the metabolic fate of IgG antibodies in vivo. Analysis of the interaction between FcRn and IgG in vitro might provide insight into the structural and functional integrity of therapeutic IgG that may affect pharmacokinetics (PK) in vivo. We developed a standardized pH gr...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.24981

    authors: Schlothauer T,Rueger P,Stracke JO,Hertenberger H,Fingas F,Kling L,Emrich T,Drabner G,Seeber S,Auer J,Koch S,Papadimitriou A

    更新日期:2013-07-01 00:00:00

  • Immunotherapy for Alzheimer disease.

    abstract::Immunotherapy approaches for Alzheimer disease currently are among the leading therapeutic directions for the disease. Active and passive immunotherapy against the beta-amyloid peptides that aggregate and accumulate in the brain of those afflicted by the disease have been shown by numerous groups to reduce plaque path...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.1.2.7829

    authors: Gouras GK

    更新日期:2009-03-01 00:00:00

  • A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis.

    abstract::Colorectal cancer represents the second most common cause of cancer-related death. The human A33 transmembrane glycoprotein is a validated tumor-associated antigen, expressed in 95% of primary and metastatic colorectal cancers. Using phage display technology, we generated a human monoclonal antibody (termed A2) specif...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1714371

    authors: Murer P,Plüss L,Neri D

    更新日期:2020-01-01 00:00:00

  • Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.

    abstract::Immunoglobulins and T cell receptors (TCRs) share common sequences and structures. With the goal of creating novel bispecific antibodies (BsAbs), we generated chimeric molecules, denoted IgG_TCRs, where the Fv regions of several antibodies were fused to the constant domains of the α/β TCR. Replacing CH1 with Cα and CL...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1007826

    authors: Wu X,Sereno AJ,Huang F,Zhang K,Batt M,Fitchett JR,He D,Rick HL,Conner EM,Demarest SJ

    更新日期:2015-01-01 00:00:00

  • Reconstructing and mining the B cell repertoire with ImmunediveRsity.

    abstract::The B cell antigen receptor repertoire is highly diverse and constantly modified by clonal selection. High-throughput DNA sequencing (HTS) of the lymphocyte repertoire (Rep-Seq) represents a promising technology to explore such diversity ex-vivo and assist in the identification of antigen-specific antibodies based on ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1026502

    authors: Cortina-Ceballos B,Godoy-Lozano EE,Sámano-Sánchez H,Aguilar-Salgado A,Velasco-Herrera Mdel C,Vargas-Chávez C,Velázquez-Ramírez D,Romero G,Moreno J,Téllez-Sosa J,Martínez-Barnetche J

    更新日期:2015-01-01 00:00:00

  • Regulation of T cell response by blocking the ICOS signal with the B7RP-1-specific small antibody fragment isolated from human antibody phage library.

    abstract::A costimulatory signal is required for the full activation of T cells, in addition to the antigen-specific signal via the T cell receptor. The inducible costimulator, ICOS is one of the costimulatory molecules that play an essential role in this process, particularly in the expansion or the development of effector T c...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.1.5.9633

    authors: Maeda M,Ito Y,Hatanaka T,Hashiguchi S,Torikai M,Nakashima T,Sugimura K

    更新日期:2009-09-01 00:00:00

  • Adsorption behavior of a human monoclonal antibody at hydrophilic and hydrophobic surfaces.

    abstract::One aspiration for the formulation of human monoclonal antibodies (mAb) is to reach high solution concentrations without compromising stability. Protein surface activity leading to instability is well known, but our understanding of mAb adsorption to the solid-liquid interface in relevant pH and surfactant conditions ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.22522

    authors: Couston RG,Skoda MW,Uddin S,van der Walle CF

    更新日期:2013-01-01 00:00:00

  • Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.

    abstract::Biological therapies have revolutionized the treatment of several cancers and systemic immune-mediated inflammatory conditions. Expiry of patents protecting a number of biologics has provided the opportunity to commercialize highly similar versions, known as biosimilars. Biosimilars are approved by regulatory agencies...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.1080/19420862.2018.1484977

    authors: Scheinberg M,Pineda C,Castañeda-Hernández G,Zarbá JJ,Damião A,Arantes LH Jr,Jacobs I

    更新日期:2018-08-01 00:00:00

  • Galactosylation variations in marketed therapeutic antibodies.

    abstract::There are currently ~25 recombinant full-length IgGs (rIgGs) in the market that have been approved by regulatory agencies as biotherapeutics to treat various human diseases. Most of these are based on IgG1k framework and are either chimeric, humanized or human antibodies manufactured using either Chinese hamster ovary...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.19868

    authors: Raju TS,Jordan RE

    更新日期:2012-05-01 00:00:00

  • A method to confer Protein L binding ability to any antibody fragment.

    abstract::Recombinant antibody single-chain variable fragments (scFv) are difficult to purify homogeneously from a protein complex mixture. The most effective, specific and fastest method of purification is an affinity chromatography on Protein L (PpL) matrix. This protein is a multi-domain bacterial surface protein that is abl...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1116657

    authors: Lakhrif Z,Pugnière M,Henriquet C,di Tommaso A,Dimier-Poisson I,Billiald P,Juste MO,Aubrey N

    更新日期:2016-01-01 00:00:00

  • The making of bispecific antibodies.

    abstract::During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, including small molecules composed solely of the antigen-binding sites of two antibo...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.1080/19420862.2016.1268307

    authors: Brinkmann U,Kontermann RE

    更新日期:2017-02-01 00:00:00

  • Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study.

    abstract::Process intensification has shown great potential to increase productivity and reduce costs in biomanufacturing. This case study describes the evolution of a manufacturing process from a conventional processing scheme at 1000-L scale (Process A, n = 5) to intensified processing schemes at both 1000-L (Process B, n = 8...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1770669

    authors: Xu J,Xu X,Huang C,Angelo J,Oliveira CL,Xu M,Xu X,Temel D,Ding J,Ghose S,Borys MC,Li ZJ

    更新日期:2020-01-01 00:00:00

  • Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models.

    abstract::The development of antibody therapeutics relies on animal models that accurately recapitulate disease biology. Syngeneic mouse models are increasingly used with new molecules to capture the biology of complex cancers and disease states, and to provide insight into the role of the immune system. The establishment of sy...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1685350

    authors: Wang F,Tsai JC,Davis JH,Chau B,Dong J,West SM,Hogan JM,Wheeler ML,Bee C,Morishige W,Cayton T,David-Brown D,Zhang C,Kozhich A,Sproul T,Dollinger G,Rajpal A,Strop P

    更新日期:2020-01-01 00:00:00

  • Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.

    abstract::Monoclonal antibodies play an increasingly important role for the development of new drugs across multiple therapy areas. The term 'developability' encompasses the feasibility of molecules to successfully progress from discovery to development via evaluation of their physicochemical properties. These properties includ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1743053

    authors: Bailly M,Mieczkowski C,Juan V,Metwally E,Tomazela D,Baker J,Uchida M,Kofman E,Raoufi F,Motlagh S,Yu Y,Park J,Raghava S,Welsh J,Rauscher M,Raghunathan G,Hsieh M,Chen YL,Nguyen HT,Nguyen N,Cipriano D,Fayadat-Dilma

    更新日期:2020-01-01 00:00:00

  • Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies.

    abstract::Although there are currently more than 30 antibody-drug conjugates (ADC) in clinical development for the treatment of blood cancers and solid tumors, comparison of their clinical pharmacokinetics (PK) is challenging because of the large number of, and differences between, the targets, ADC constructs, dosing regimens, ...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.28965

    authors: Deslandes A

    更新日期:2014-07-01 00:00:00

  • Improved in vitro and in vivo activity against CD303-expressing targets of the chimeric 122A2 antibody selected for specific glycosylation pattern.

    abstract::Plasmacytoid dendritic cells (pDCs) play a central role for both innate and adaptive antiviral responses, as they direct immune responses through their unique ability to produce substantial concentrations of type I interferon (IFNs) upon viral encounter while also activating multiple immune cells, including macrophage...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1451283

    authors: Fournier N,Jacque E,Fontayne A,Derache D,Dupont G,Verhaeghe L,Baptista L,Dehenne A,Dezetter AS,Terrier A,Longue A,Pochet-Beghin V,Beghin C,Chtourou S,de Romeuf C

    更新日期:2018-05-01 00:00:00

  • Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.

    abstract::MPDL3280A is a human monoclonal antibody that targets programmed cell death-1 ligand 1 (PD-L1), and exerts anti-tumor activity mainly by blocking PD-L1 interaction with programmed cell death-1 (PD-1) and B7.1. It is being investigated as a potential therapy for locally advanced or metastatic malignancies. The purpose ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1136043

    authors: Deng R,Bumbaca D,Pastuskovas CV,Boswell CA,West D,Cowan KJ,Chiu H,McBride J,Johnson C,Xin Y,Koeppen H,Leabman M,Iyer S

    更新日期:2016-01-01 00:00:00

  • Functional domain analysis of SOX18 transcription factor using a single-chain variable fragment-based approach.

    abstract::Antibodies are routinely used to study the activity of transcription factors, using various in vitro and in vivo approaches such as electrophoretic mobility shift assay, enzyme-linked immunosorbent assay, genome-wide method analysis coupled with next generation sequencing, or mass spectrometry. More recently, a new ap...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1451288

    authors: Fontaine FR,Goodall S,Prokop JW,Howard CB,Moustaqil M,Kumble S,Rasicci DT,Osborne GW,Gambin Y,Sierecki E,Jones ML,Zuegg J,Mahler S,Francois M

    更新日期:2018-05-01 00:00:00

  • EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies.

    abstract::Bispecific antibody therapeutics can expand the functionality of a conventional monoclonal antibody drug because they can bind multiple antigens. However, their great potential is counterbalanced by the challenges faced in their production. The classic asymmetric bispecific containing an Fc requires the expression of ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1519631

    authors: Cooke HA,Arndt J,Quan C,Shapiro RI,Wen D,Foley S,Vecchi MM,Preyer M

    更新日期:2018-11-01 00:00:00

  • Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis.

    abstract::Site-specific antibody-drug conjugates (ADCs) are designed to overcome the heterogeneity observed with first-generation ADCs that use random conjugation to surface-exposed lysine residues or conjugation to interchain disulfide bonds. Despite significantly enhanced homogeneity, however, the production of site-specific ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1624127

    authors: Cao M,De Mel N,Jiao Y,Howard J,Parthemore C,Korman S,Thompson C,Wendeler M,Liu D

    更新日期:2019-08-01 00:00:00

  • Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis.

    abstract::Much data support a role for central nervous system antigen-specific antibodies in the pathogenesis of multiple sclerosis (MS). The effects of inducing a decrease in (auto)antibody levels on MS or experimental autoimmune encephalomyelitis (EAE) through specific blockade of FcRn, however, remain unexplored. We recently...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.25439

    authors: Challa DK,Bussmeyer U,Khan T,Montoyo HP,Bansal P,Ober RJ,Ward ES

    更新日期:2013-09-01 00:00:00

  • Generation of human single-chain variable fragment antibodies specific to dengue virus non-structural protein 1 that interfere with the virus infectious cycle.

    abstract::Severe forms of dengue virus (DENV) infection frequently cause high case fatality rate. Currently, there is no effective vaccine against the infection. Clinical cases are given only palliative treatment as specific anti-DENV immunotherapy is not available and it is urgently required. In this study, human single-chain ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.27874

    authors: Poungpair O,Bangphoomi K,Chaowalit P,Sawasdee N,Saokaew N,Choowongkomon K,Chaicumpa W,Yenchitsomanus PT

    更新日期:2014-03-01 00:00:00

  • Influence of glycosylation pattern on the molecular properties of monoclonal antibodies.

    abstract::Glycosylation is an important post-translational modification during protein production in eukaryotic cells, and it is essential for protein structure, stability, half-life, and biological functions. In this study, we produced various monoclonal antibody (mAb) glycoforms from Chinese hamster ovary (CHO) cells, includi...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.28588

    authors: Zheng K,Yarmarkovich M,Bantog C,Bayer R,Patapoff TW

    更新日期:2014-05-01 00:00:00

  • Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc.

    abstract::The development of alternative therapeutic strategies to tumor necrosis factor (TNF)-blocking antibodies for the treatment of inflammatory diseases has generated increasing interest. In particular, selective inhibition of TNF receptor 1 (TNFR1) promises a more precise intervention, tackling only the pro-inflammatory r...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1596512

    authors: Richter F,Seifert O,Herrmann A,Pfizenmaier K,Kontermann RE

    更新日期:2019-05-01 00:00:00

  • Specific and high-resolution identification of monoclonal antibody fragments detected by capillary electrophoresis-sodium dodecyl sulfate using reversed-phase HPLC with top-down mass spectrometry analysis.

    abstract::In recent years, capillary electrophoresis-sodium dodecyl sulfate (cSDS) has been widely used for high resolution separation and quantification of the fragments and aggregates of monoclonal antibodies (mAbs) to ensure the quality of mAb therapeutics. However, identification of the low-molecular-weight (LMW) and high-m...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1646554

    authors: Wang WH,Cheung-Lau J,Chen Y,Lewis M,Tang QM

    更新日期:2019-10-01 00:00:00

  • Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.

    abstract::Pharmacokinetic (PK) testing of a humanized (κI, VH3 framework) and affinity matured anti-hepatitis C virus E2-glycoprotein (HCV-E2) antibody (hu5B3.κ1VH3.v3) in rats revealed unexpected fast clearance (34.9 mL/day/kg). This antibody binds to the rat recycling receptor FcRn as expected for a human IgG1 antibody and do...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.29809

    authors: Li B,Tesar D,Boswell CA,Cahaya HS,Wong A,Zhang J,Meng YG,Eigenbrot C,Pantua H,Diao J,Kapadia SB,Deng R,Kelley RF

    更新日期:2014-01-01 00:00:00

  • Selection and verification of antibodies against the cytoplasmic domain of M2 of influenza, a transmembrane protein.

    abstract::Interactions between the cytoplasmic domains of viral transmembrane proteins and host machinery often determine the outcome of viral infection. The M2 protein of influenza A has been identified as a key player in autophagy-mediated viral replication. Here, we describe the engineering and validation of an antibody spec...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1843754

    authors: Velappan N,Micheva-Viteva S,Adikari SH,Waldo GS,Lillo AM,Bradbury ARM

    更新日期:2020-01-01 00:00:00

  • Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system.

    abstract::We describe protein synthesis, folding and assembly of antibody fragments and full-length aglycosylated antibodies using an Escherichia coli-based open cell-free synthesis (OCFS) system. We use DNA template design and high throughput screening at microliter scale to rapidly optimize production of single-chain Fv (scFv...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.4.2.19202

    authors: Yin G,Garces ED,Yang J,Zhang J,Tran C,Steiner AR,Roos C,Bajad S,Hudak S,Penta K,Zawada J,Pollitt S,Murray CJ

    更新日期:2012-03-01 00:00:00

  • Certolizumab pegol.

    abstract::Certolizumab pegol (Cimzia(®)) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab') of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pe...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.2.2.11271

    authors: Goel N,Stephens S

    更新日期:2010-03-01 00:00:00